No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
196 |
4. Check minimum number of eventsNone |
196 |
5. Include endpointsNone |
196 |
6. Filter based on genotype QC (FinnGen only) |
179 |
Control definitions (FinnGen only)
- Control exclude
- H7_VISUALDISTBLIND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H54
- Name in latin
- Amaurosis oculorum amborum
Similar endpoints
↥List of similar endpoints to
Blindness or visual impairment, binocular
based on the number of shared cases.
Similar with more cases:
- Visual impairment including blindness (binocular or monocular)
- Visual disturbances and blindness
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2294 | 1145 | 1123 |
| Only index persons | 1910 | 996 | 914 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 62.61 | 64.75 | 60.11 |
| Only index persons | 61.83 | 64.18 | 59.26 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 179 | 92 | 87 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.04 |
| Median age at first event (years) | 60.82 | 56.55 | 65.33 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 187
- Matched controls
- 1869
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H54.0
ICD-10 Finland
Blindness, binocular
+∞
270.6
187
*
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
708.1
55.6
52
*
S01ED01
ATC
timolol; ophthalmic
13.8
38.4
39
35
Z3229
NOMESCO Finland
Other healthcare associate professional
7.6
31.5
54
95
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
37.4
27.0
34
11
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
7.4
26.1
44
75
F94
ICPC
Blindness
+∞
25.6
24
*
H54.1
ICD-10 Finland
Severe visual impairment, binocular
+∞
23.4
22
*
114
Kela drug reimbursment
Glaucoma
5.8
22.6
50
111
S01ED51
ATC
timolol, combinations; ophthalmic
6.3
21.9
43
85
H54.4
ICD-10 Finland
Blindness, monocular
+∞
21.2
20
*
H35.5
ICD-10 Finland
Hereditary retinal dystrophy
235.0
21.0
21
*
R3120
NOMESCO Finland
Training in mobility skills
235.0
21.0
21
*
S01EC01
ATC
acetazolamide; systemic
19.3
20.5
31
19
XCK00
NOMESCO Finland
Perimetry
6.9
20.5
35
60
A28
ICPC
Limited function/disability NOS
4.1
19.0
73
250
S01EE01
ATC
latanoprost; ophthalmic
5.9
17.5
35
70
AA1AD
NOMESCO Finland
CT of head and brain
3.7
17.4
86
347
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.5
16.8
50
140
Z96.1
ICD-10 Finland
Presence of intraocular lens
4.0
16.6
61
200
XCK10
NOMESCO Finland
Photography of fundus of eye
4.9
15.9
41
102
S01EA05
ATC
brimonidine; ophthalmic
14.2
15.4
26
21
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.7
15.1
66
242
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
6.1
14.5
27
50
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
5.2
14.4
33
74
A10AA01, ,
ATC
7.2
14.0
22
34
H16.0
ICD-10 Finland
Corneal ulcer
6.1
14.0
26
48
H47.2
ICD-10 Finland
Optic atrophy
+∞
13.7
13
*
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
150.4
13.6
14
*
A10AB04
ATC
insulin lispro; parenteral
6.6
12.9
22
37
A10AB01
ATC
insulin (human); parenteral
5.9
12.9
25
48
H53.1
ICD-10 Finland
Subjective visual disturbances
15.8
12.6
20
14
CKD40
NOMESCO Finland
Endophotocoagulation of retina
15.8
12.6
20
14
Z2446
NOMESCO Finland
Social worker
5.4
12.6
27
57
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
3.0
12.5
106
564
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
11.2
12.4
23
23
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
12.3
55
202
A10AA02, ,
ATC
5.5
12.1
25
51
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
50.1
12.0
14
*
CHF05
NOMESCO Finland
Transscleral laser coagulation of ciliary body
32.4
11.8
15
5
H3603, E103,
ICD-10 Finland
32.4
11.8
15
5
Z02.4
ICD-10 Finland
Examination for driving licence
0.1
11.8
*
374
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.4
11.7
32
83
Z90.0
ICD-10 Finland
Acquired absence of part of head and neck
+∞
11.6
11
*
H53.4
ICD-10 Finland
Visual field defects
127.5
11.6
12
*
H44.5
ICD-10 Finland
Degenerated conditions of globe
127.5
11.6
12
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
11.2
40
126
SPAT1229
SPAT
Assessment of need for aid
4.6
11.1
29
72
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
46.2
11.1
13
*
CKD15
NOMESCO Finland
Injection of vitreous substitute
46.2
11.1
13
*
S01BC03
ATC
diclofenac; ophthalmic
19.3
10.9
16
9
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
23.1
10.9
15
7
H54.3
ICD-10 Finland
Mild or no visual impairment, binocular
116.2
10.5
11
*
H33.4
ICD-10 Finland
Traction detachment of retina
+∞
10.5
10
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.4
10.4
45
160
S01BA01
ATC
dexamethasone; ophthalmic
9.3
10.4
21
25
H36.03
ICD-10 Finland
Proliferative diabetic retinopathy
21.5
10.0
14
7
127
Kela drug reimbursment
Transplant complication
21.5
10.0
14
7
H54.7
ICD-10 Finland
Unspecified visual loss
27.7
10.0
13
5
L28
ICPC
Limited function/disability (L)
3.0
9.9
56
233
H43.1
ICD-10 Finland
Vitreous haemorrhage
10.9
9.8
18
18
H40.13
ICD-10 Finland
Chronic glaucoma with open ventricular angle
5.1
9.5
21
45
37520
ICD-8 Finland
Glaucoma, Secondary
105.1
9.5
10
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
23.1
9.5
13
6
3690A
ICD-9 Finland
Blindness and low vision, Profound impairment, both eyes
+∞
9.4
9
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
14.7
9.4
15
11
H04AA01
ATC
glucagon; nasal, parenteral
9.1
9.3
19
23
WX140
NOMESCO Finland
Parabulbar anesthesy
5.0
9.3
21
46
N08.39
ICD-10 Finland
Glomerular disorders in diabetes mellitus microalbuminuria
38.7
9.1
11
*
Z94.0
ICD-10 Finland
Kidney transplant status
38.7
9.1
11
*
S01FA01
ATC
atropine; ophthalmic
38.7
9.1
11
*
S01EC04
ATC
brinzolamide; ophthalmic
5.1
9.1
20
43
CKD20
NOMESCO Finland
Removal of vitreous body substitute
25.5
9.0
12
5
A10AC01
ATC
insulin (human); parenteral
3.5
8.9
34
111
A10AE05
ATC
insulin detemir; parenteral
4.5
8.8
23
57
S01EX03, ,
ATC
10.8
8.7
16
16
TK800
NOMESCO Finland
Hemodialysis
13.6
8.5
14
11
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
94.1
8.5
9
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
94.1
8.5
9
*
74483
ICD-8 Finland
Congenital anomalies of eye, Retinitis pigmentosa
+∞
8.4
8
*
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
4.7
8.4
20
46
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
8.3
82
448
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
35.0
8.2
10
*
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
23.2
8.1
11
5
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
8.0
7.9
17
23
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.3
7.8
21
53
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
47.0
7.8
9
*
N18.0
ICD-10 Finland
End-stage renal disease
47.0
7.8
9
*
ZXD05
NOMESCO Finland
Urgent procedure
2.5
7.8
73
387
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.2
7.6
16
21
H53.9
ICD-10 Finland
Visual disturbance, unspecified
8.9
7.5
15
18
H33.0
ICD-10 Finland
Retinal detachment with retinal break
6.7
7.4
18
29
S01EC54
ATC
brinzolamide, combinations; ophthalmic
11.5
7.4
13
12
CS494
NOMESCO Finland
Other visual field testing
11.5
7.4
13
12
L04AA01
ATC
[U] ciclosporin
16.6
7.3
11
7
T89
ICPC
Diabetes insulin dependent
4.4
7.3
19
47
SPAT1231
SPAT
Assessment of adjustments needed in living environment
8.5
7.3
15
19
Z94.7
ICD-10 Finland
Corneal transplant status
31.3
7.2
9
*
S01BA07
ATC
fluorometholone; ophthalmic
12.7
7.2
12
10
NH1BA
NOMESCO Finland
Ankle extensive X-ray examination
10.6
7.2
13
13
R4120
NOMESCO Finland
Occupational therapy
4.3
7.1
19
48
SPAT1033
SPAT
Irrigation or wax removal of outer auditory canal
2.6
7.0
48
218
V03AE01
ATC
polystyrene sulfonate; oral
14.5
7.0
11
8
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
7.0
43
185
S01EC03
ATC
dorzolamide; ophthalmic
11.6
6.9
12
11
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
6.9
84
494
OAB43, ,
SPAT
0.2
6.9
7
317
E10.4
ICD-10 Finland
Type 1 diabetes mellitus, With neurological complications
17.5
6.8
10
6
H26.2
ICD-10 Finland
Complicated cataract
17.5
6.8
10
6
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
17.5
6.8
10
6
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.1
6.8
30
107
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
2.3
6.8
84
496
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
4.3
6.8
18
45
A11CC03
ATC
alfacalcidol; systemic
8.3
6.7
14
18
H46
ICD-10 Finland
Optic neuritis
23.5
6.7
9
*
S01BC05
ATC
ketorolac; ophthalmic
4.5
6.7
17
41
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.3
6.7
27
91
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
9.2
6.7
13
15
A10AE04
ATC
insulin glargine; parenteral
2.9
6.6
33
127
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.3
6.5
70
388
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
4.3
6.5
17
42
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
15.0
6.5
10
7
CGG45
NOMESCO Finland
Full thickness transplantation of cornea using homograft
72.2
6.5
7
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
6.4
57
292
A10AB05
ATC
insulin aspart; parenteral
3.1
6.3
28
100
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
6.3
98
629
SPAT1254
SPAT
Administration of medicine
2.6
6.3
41
181
A06AD11
ATC
lactulose; oral
2.6
6.3
41
181
37909
ICD-8 Finland
Blindness, both eyes, specifically defined
+∞
6.3
6
*
2503B
ICD-9 Finland
Diabetes mellitus, Diabetes with other coma[SOKERITAUDIN AIHEUTTAMA MUNUAISSAIRAUS,TYYPPI I]
+∞
6.3
6
*
3711
FHL
Cyclodiateria or cryocoagulation
+∞
6.3
6
*
S01EE03
ATC
bimatoprost; ophthalmic
8.1
6.2
13
17
CKD92
NOMESCO Finland
Combined vitrectomy and retinal procedure
13.1
6.2
10
8
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
6.1
41
183
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.1
6.1
17
44
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
4.1
6.1
17
44
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.6
6.1
41
184
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
90
465
2.80
10.81
3.0
2.1
261.16
231.07
u/l
0.11
85
443
55
221
3.11
10.43
13.3
5.9
1.09
1.07
mmol/l
0.15
50
195
35
125
3.21
7.95
8.4
4.1
113.38
80.87
ng/l
0.83
29
108
110
701
2.38
7.69
14.4
6.3
1.22
1.21
mmol/l
0.37
98
657
58
278
2.57
7.64
2.3
2.1
—
—
—
0
0
57
271
2.59
7.63
1.9
1.7
1174.62
1223.33
nmol/l
0.15
45
215
115
776
2.25
6.65
16.8
7.4
1.21
1.21
mmol/l
0.01
100
673
20
57
3.81
6.35
4.3
4.0
1.97
1.49
mg/l
1.24
20
51
55
281
2.35
6.16
5.3
3.3
0.82
0.81
mmol/l
0.27
50
264
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
44
4.15
6.13
5.9
2.5
0.30
0.37
iu/ml
0.38
12
25
44
206
2.48
5.96
1.7
1.9
—
—
—
0
0
9
8
11.73
5.34
8.4
3.4
—
—
—
0
0
19
59
3.47
5.33
2.6
1.8
—
—
—
0
0
49
253
2.27
5.28
4.9
2.6
2.15
2.32
g/l
1.27
44
233
103
707
2.02
5.22
9.1
4.9
33.85
35.51
g/l
1.82
88
670
116
839
2.01
4.97
7.4
6.4
9.38
12.07
umol/l
3.54
106
799
23
86
2.91
4.78
1.8
1.8
—
—
—
0
0
94
640
1.94
4.73
5.4
4.3
172.64
41.95
ng/l
0.80
78
467
97
668
1.94
4.71
2.4
2.2
104.19
97.21
pmol/l
0.61
57
365
95
663
1.88
4.31
3.9
2.7
76.53
77.47
nmol/l
0.11
87
604
7
6
12.04
4.31
1.7
1.0
—
—
—
0
0
146
1175
2.10
4.30
11.9
7.9
92.33
77.58
u/l
2.88
133
1114
18
62
3.10
4.30
2.9
2.1
—
—
—
0
0
58
344
1.99
4.29
1.8
1.8
421.78
40068920.50
pmol/l
0.50
49
292
35
172
2.27
4.19
6.0
4.8
33.20
31.14
%
0.43
25
113
27
125
2.35
3.69
2.8
2.6
9.11
6.06
ug/l
0.31
18
112
62
396
1.84
3.59
3.0
2.2
3.14
2.99
mg/l
0.20
51
348
24
109
2.38
3.42
1.9
1.7
—
—
—
0
0
31
158
2.15
3.39
11.3
8.6
—
—
—
0
0
9
19
4.92
3.28
1.1
1.9
—
—
—
0
0
33
175
2.07
3.26
2.4
3.8
4.61
8.64
umol/l
1.90
23
156
8
15
5.52
3.22
1.3
1.3
—
—
—
0
0
15
56
2.82
3.14
1.5
1.3
—
—
—
0
0
68
466
1.72
3.03
2.1
1.8
20.96
21.11
nmol/l
0.02
61
397
9
22
4.24
2.92
1.1
1.8
—
—
—
0
0
11
33
3.47
2.86
1.5
1.4
—
—
—
0
0
11
33
3.47
2.86
1.5
1.4
—
—
—
0
0
35
199
1.93
2.85
1.8
2.1
—
—
—
0
0
10
28
3.71
2.82
1.7
1.4
—
—
—
0
0
11
34
3.37
2.77
1.1
1.7
—
—
—
0
0
71
503
1.66
2.75
6.2
2.5
48.61
65.01
u/l
1.07
62
467
12
41
3.05
2.67
2.2
2.1
—
—
—
0
0
5
7
7.29
2.56
1.2
2.1
—
—
—
0
0
5
7
7.29
2.56
1.0
1.1
—
—
—
0
0
5
7
7.29
2.56
1.2
2.1
—
—
—
0
0
5
8
6.38
2.38
1.2
2.0
—
—
—
0
0
5
8
6.38
2.38
1.4
2.0
—
—
—
0
0
5
8
6.38
2.38
1.6
1.8
—
—
—
0
0
5
8
6.38
2.38
1.2
2.0
—
—
—
0
0
5
8
6.38
2.38
1.2
2.0
—
—
—
0
0
5
8
6.38
2.38
1.2
2.0
—
—
—
0
0
5
8
6.38
2.38
1.6
1.8
—
—
—
0
0
7
17
4.23
2.38
1.0
1.1
—
—
—
0
0
11
41
2.78
2.25
1.7
1.6
—
—
—
0
0
36
224
1.75
2.21
13.8
5.8
103.39
103.81
mmol/l
0.24
36
224
153
1353
1.72
2.15
6.5
5.2
1.93
1.95
mu/l
0.07
136
1233
166
1504
1.92
2.12
39.6
19.8
4.02
3.97
mmol/l
1.34
159
1473
166
1505
1.91
2.10
40.1
19.7
139.45
139.64
mmol/l
0.46
159
1479
5
10
5.10
2.08
1.6
1.8
—
—
—
0
0
5
10
5.10
2.08
1.6
1.8
—
—
—
0
0
12
50
2.49
2.07
1.3
1.2
—
—
—
0
0
14
63
2.32
2.06
3.5
2.7
24.59
24.63
mmol/l
0.01
14
63
25
142
1.88
2.05
8.4
3.4
5.20
4.35
kpa
0.71
25
137
12
51
2.44
1.99
1.3
1.2
—
—
—
0
0
45
307
1.61
1.96
3.8
4.0
29.45
225.04
ng/l
1.40
37
249
5
11
4.63
1.95
2.6
1.8
—
—
—
0
0
6
16
3.83
1.95
1.3
1.9
—
—
—
0
0
6
16
3.83
1.95
1.3
1.9
—
—
—
0
0
6
16
3.83
1.95
1.3
1.9
—
—
—
0
0
12
52
2.40
1.92
1.2
1.7
—
—
—
0
0
28
172
1.74
1.80
3.7
3.5
—
—
—
0
0
6
18
3.41
1.76
2.0
1.8
—
—
—
0
0
6
18
3.41
1.76
2.0
1.8
—
—
—
0
0
6
18
3.41
1.76
2.0
1.8
—
—
—
0
0
6
18
3.41
1.76
2.0
1.8
—
—
—
0
0
108
905
1.46
1.73
11.9
9.9
4.63
4.17
e9/l
0.48
96
799
5
13
3.92
1.72
1.0
1.0
—
—
—
0
0
161
1468
1.69
1.71
33.3
16.7
25.95
24.44
mg/l
0.23
141
1210
129
1121
1.48
1.70
5.4
4.3
15.21
14.76
pmol/l
1.20
115
1019
6
19
3.22
1.67
2.0
1.8
—
—
—
0
0
6
19
3.22
1.67
1.7
3.9
428.00
915.32
mg
—
6
19
6
19
3.22
1.67
2.0
1.8
—
—
—
0
0
8
32
2.56
1.61
19.1
1.1
1.12
0.81
nmol/l
—
8
27
11
50
2.27
1.60
1.6
1.2
—
—
—
0
0
64
496
1.44
1.52
4.9
4.1
0.00
0.01
estimate
0.50
18
171
7
28
2.56
1.46
1.3
1.1
—
—
—
0
0
17
281
0.57
1.44
1.3
1.3
12.00
29.46
iu/ml
—
5
84
50
375
1.45
1.40
1.3
1.3
0.79
1.33
u/ml
0.52
11
108
47
349
1.46
1.38
4.4
2.3
—
—
—
0
0
68
541
1.40
1.38
5.6
3.6
2.36
2.36
mmol/l
0.08
58
495
112
969
1.39
1.37
3.8
3.4
46.08
48.46
u/l
0.18
102
919
66
523
1.40
1.37
3.5
3.6
2181.96
1534.99
ng/l
0.48
60
434
65
514
1.40
1.36
7.0
4.0
16.83
10.21
mg/mmol
0.63
47
346
8
34
2.41
1.31
1.5
1.7
—
—
—
0
0
15
85
1.83
1.27
1.5
1.4
—
—
—
0
0
19
116
1.71
1.27
2.7
3.0
63.91
64.89
ml/min/173m2
0.04
11
44
6
26
2.35
1.19
1.8
2.3
2.85
147.06
u/ml
—
6
26
164
1536
1.55
1.14
17.2
11.9
27.62
25.29
u/l
0.90
157
1496
7
31
2.30
1.11
1.6
1.9
—
—
—
0
0
165
1550
1.54
1.10
40.1
21.8
90.51
79.67
umol/l
1.70
159
1528
34
249
1.45
1.08
4.0
3.2
3.02
1.96
e6/l
0.39
22
125
151
1398
1.41
1.06
6.6
5.1
6.49
6.03
mmol/l
1.42
136
1289
47
367
1.37
1.04
4.4
4.4
1.02
1.02
kg/l
0.11
28
243
9
49
1.88
1.00
1.2
1.7
—
—
—
0
0
96
838
1.30
0.98
4.8
4.1
69.55
8.33
estimate
0.41
20
195
0
31
0.00
0.97
0.0
1.1
—
1.02
—
0
19
124
1121
1.31
0.97
5.0
4.3
17.45
11.94
mm/h
2.59
114
1041
6
27
2.26
0.94
1.5
1.9
—
—
—
0
0
95
835
1.28
0.90
4.8
4.1
0.00
0.00
estimate
-0.00
19
187
96
845
1.28
0.90
4.8
4.1
0.00
0.00
estimate
-0.00
18
177
8
42
1.94
0.90
1.5
1.7
—
—
—
0
0
167
1587
1.48
0.88
46.9
25.3
245.43
245.98
e9/l
0.04
162
1560
167
1588
1.48
0.87
47.3
25.2
91.35
91.26
fl
0.08
162
1572
167
1589
1.47
0.85
47.3
25.3
4.29
4.47
e12/l
3.82
162
1553
167
1589
1.47
0.85
47.9
25.6
38.66
40.18
%
3.03
162
1571
147
1371
1.33
0.85
9.9
6.6
43.45
39.97
mmol/mol
2.33
131
1290
49
398
1.31
0.84
4.2
3.2
388.62
351.91
umol/l
1.15
39
350
167
1591
1.46
0.82
47.7
25.4
128.59
134.67
g/l
4.92
162
1573
13
82
1.63
0.80
1.3
1.3
—
—
—
0
0
56
467
1.28
0.79
5.0
3.1
0.19
0.41
e6/l
1.43
46
340
0
26
0.00
0.79
0.0
3.5
—
—
—
0
0
35
273
1.35
0.79
4.2
2.9
1.46
1.11
e6/l
0.22
25
147
11
168
0.63
0.71
2.9
2.3
—
—
—
0
0
41
335
1.29
0.68
2.6
1.8
1.26
1.43
mg/l
0.17
29
273
7
43
1.65
0.67
2.0
1.3
—
—
—
0
0
78
691
1.22
0.64
3.8
2.7
—
—
estimate
—
0
0
39
324
1.26
0.57
3.7
2.9
2.47
2.46
mmol/l
0.28
33
287
73
650
1.20
0.55
4.5
4.0
0.00
0.02
estimate
0.50
17
158
6
38
1.60
0.55
6.7
2.6
13.73
16.06
%
—
6
38
10
66
1.54
0.53
1.9
2.8
—
—
—
0
0
9
65
1.40
0.51
3.0
3.6
8.56
1005.46
u/ml
—
9
57
151
1444
1.23
0.50
6.7
5.8
2.55
2.65
mmol/l
0.57
132
1337
142
1354
1.20
0.46
5.4
4.3
1.52
1.28
mmol/l
2.25
121
1238
11
150
0.72
0.43
2.6
2.2
—
—
—
0
0
145
1392
1.18
0.39
27.9
16.6
73.72
78.83
ml/min/173m2
1.62
134
1301
147
1421
1.16
0.32
6.2
5.1
4.44
4.57
mmol/l
0.60
129
1319
17
206
0.81
0.31
1.8
1.4
—
—
—
0
0
146
1412
1.15
0.30
6.3
5.0
1.31
1.45
mmol/l
4.70
127
1300
7
56
1.26
0.30
1.1
2.4
6.48
3.12
mg/l
—
7
42
11
85
1.31
0.28
8.5
2.6
1.25
1.13
%
0.20
11
85
33
371
0.87
0.27
5.6
4.6
29.60
22.81
%
1.22
18
186
10
78
1.30
0.24
1.1
1.0
—
—
—
0
0
5
37
1.36
0.23
1.2
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
3.4
—
977.50
—
0
10
0
12
0.00
0.21
0.0
1.3
—
196.41
—
0
12
53
493
1.10
0.21
5.2
5.4
2.23
2.08
ug/l
0.14
42
435
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
25
275
0.89
0.16
3.2
3.0
1.09
0.80
ug/l
1.15
16
179
61
595
1.04
0.05
2.1
1.9
1.48
1.36
mmol/l
0.42
50
499
91
897
1.03
0.04
3.3
3.1
—
—
—
0
0
26
254
1.03
0.00
1.7
1.6
—
—
—
0
0
13
125
1.04
0.00
1.1
1.3
—
—
—
0
0
48
475
1.01
0.00
4.1
3.4
0.00
0.01
estimate
0.50
17
147
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.5
—
16.95
—
0
8
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.4
—
9.60
—
0
8
0
7
0.00
0.00
0.0
6.4
—
276.43
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
8.75
—
0
8
0
5
0.00
0.00
0.0
1.2
—
7.28
—
0
5
0
8
0.00
0.00
0.0
3.4
—
4.71
—
0
8
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.24
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
78.13
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_VISIMPBILATERAL and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_VISIMPBILATERAL | 2.117 [1.63, 2.75] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.088 |
During the follow-up period (1.1.1998 — 31.12.2019), 416 out of 1022 females with H7_VISIMPBILATERAL died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_VISIMPBILATERAL | 2.19 [1.67, 2.87] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.014 |
During the follow-up period (1.1.1998 — 31.12.2019), 413 out of 986 males with H7_VISIMPBILATERAL died.
Mortality risk
Mortality risk for people of age
years, who have H7_VISIMPBILATERAL.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.167% | 0.477% |
| 5 | 0.988% | 2.345% |
| 10 | 2.677% | 6.198% |
| 15 | 5.119% | 11.656% |
| 20 | 9.06% | 20.056% |
Relationships between endpoints
↥Index endpoint: H7_VISIMPBILATERAL – Blindness or visual impairment, binocular
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data